Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Brad H. Rovin, Dawn J. Caster, Daniel C. Cattran, Keisha L. Gibson, Jonathan J. Hogan, Marcus J. Moeller, Dario Roccatello, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayer, Jürgen Floege, for Conference Participants

Research output: Contribution to journalArticleOtherpeer-review

38 Citations (Scopus)


In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody–associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

Original languageEnglish
Pages (from-to)281-295
Number of pages15
JournalKidney International
Issue number2
Publication statusPublished - 1 Feb 2019
Externally publishedYes


  • anti-neutrophil cytoplasmic antibody–associated vasculitis
  • C3 glomerulopathy
  • focal and segmental glomerulosclerosis
  • lupus nephritis
  • membranoproliferative glomerulonephritis
  • minimal change disease
  • monoclonal gammopathies of renal significance

Cite this